Bayer AG (BAYN)

ESG outlook clouded by potential Monsanto liability?

After the merger with Monsanto and the verdict in a legacy lawsuit, Bayer stock is at a multi-year low. In this research brief, we explore:

  • Whether this damaging litigation risk is the beginning of an ongoing theme, or just a discrete but non-repeating scenario.
  • The increasing number of cancer cases against Monsanto.
  • ESG issues that are now woven into Bayer’s fundamental outlook.
  • Other potential risks within Bayer's agriculture business.

Complete the form to download Truvalue Labs' research brief on Bayer AG.